GTBP
Price
$2.99
Change
-$0.00 (-0.00%)
Updated
Nov 6 closing price
MDGL
Price
$338.22
Change
-$0.00 (-0.00%)
Updated
Nov 6 closing price
111 days until earnings call
Ad is loading...

GTBP vs MDGL

Header iconGTBP vs MDGL Comparison
Open Charts GTBP vs MDGLBanner chart's image
GT Biopharma
Price$2.99
Change-$0.00 (-0.00%)
Volume$9.33K
CapitalizationN/A
Madrigal Pharmaceuticals
Price$338.22
Change-$0.00 (-0.00%)
Volume$592.44K
CapitalizationN/A
View a ticker or compare two or three
GTBP vs MDGL Comparison Chart
Loading...
GTBP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
GTBP vs. MDGL commentary
Nov 08, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GTBP is a Buy and MDGL is a Buy.

COMPARISON
Comparison
Nov 08, 2024
Stock price -- (GTBP: $2.99 vs. MDGL: $338.31)
Brand notoriety: GTBP and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GTBP: 52% vs. MDGL: 141%
Market capitalization -- GTBP: $6.68M vs. MDGL: $7.38B
GTBP [@Biotechnology] is valued at $6.68M. MDGL’s [@Biotechnology] market capitalization is $7.38B. The market cap for tickers in the [@Biotechnology] industry ranges from $486.24B to $0. The average market capitalization across the [@Biotechnology] industry is $2.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GTBP’s FA Score shows that 1 FA rating(s) are green whileMDGL’s FA Score has 1 green FA rating(s).

  • GTBP’s FA Score: 1 green, 4 red.
  • MDGL’s FA Score: 1 green, 4 red.
According to our system of comparison, both GTBP and MDGL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GTBP’s TA Score shows that 6 TA indicator(s) are bullish while MDGL’s TA Score has 5 bullish TA indicator(s).

  • GTBP’s TA Score: 6 bullish, 4 bearish.
  • MDGL’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, GTBP is a better buy in the short-term than MDGL.

Price Growth

GTBP (@Biotechnology) experienced а -0.66% price change this week, while MDGL (@Biotechnology) price change was +56.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.10%. For the same industry, the average monthly price growth was +12.99%, and the average quarterly price growth was +10.90%.

Reported Earning Dates

GTBP is expected to report earnings on May 13, 2024.

MDGL is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (+3.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($7.38B) has a higher market cap than GTBP($6.68M). MDGL YTD gains are higher at: 46.214 vs. GTBP (-60.915). GTBP has higher annual earnings (EBITDA): -11.35M vs. MDGL (-502.65M). MDGL has more cash in the bank: 999M vs. GTBP (9.25M). GTBP has less debt than MDGL: GTBP (0) vs MDGL (119M). MDGL has higher revenues than GTBP: MDGL (76.8M) vs GTBP (0).
GTBPMDGLGTBP / MDGL
Capitalization6.68M7.38B0%
EBITDA-11.35M-502.65M2%
Gain YTD-60.91546.214-132%
P/E RatioN/AN/A-
Revenue076.8M-
Total Cash9.25M999M1%
Total Debt0119M-
FUNDAMENTALS RATINGS
GTBP vs MDGL: Fundamental Ratings
GTBP
MDGL
OUTLOOK RATING
1..100
2428
VALUATION
overvalued / fair valued / undervalued
1..100
21
Undervalued
70
Overvalued
PROFIT vs RISK RATING
1..100
10025
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
4235
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GTBP's Valuation (21) in the null industry is somewhat better than the same rating for MDGL (70) in the Pharmaceuticals Other industry. This means that GTBP’s stock grew somewhat faster than MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (25) in the Pharmaceuticals Other industry is significantly better than the same rating for GTBP (100) in the null industry. This means that MDGL’s stock grew significantly faster than GTBP’s over the last 12 months.

MDGL's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as GTBP (98) in the null industry. This means that MDGL’s stock grew similarly to GTBP’s over the last 12 months.

MDGL's Price Growth Rating (35) in the Pharmaceuticals Other industry is in the same range as GTBP (42) in the null industry. This means that MDGL’s stock grew similarly to GTBP’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as GTBP (100) in the null industry. This means that MDGL’s stock grew similarly to GTBP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GTBPMDGL
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 4 days ago
86%
Bullish Trend 2 days ago
76%
Declines
ODDS (%)
Bearish Trend 8 days ago
90%
Bearish Trend 16 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
79%
View a ticker or compare two or three
Ad is loading...
GTBP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IYT74.023.46
+4.90%
iShares Transportation Average ETF
BAUG43.550.67
+1.57%
Innovator U.S. Equity Buffer ETF Aug
EEMO16.890.16
+0.93%
Invesco S&P Emerging Markets Mom ETF
EWUS36.87-0.36
-0.97%
iShares MSCI United Kingdom Small-Cp ETF
BBEU58.34-1.36
-2.28%
JPMorgan BetaBuilders Europe ETF

GTBP and

Correlation & Price change

A.I.dvisor indicates that over the last year, GTBP has been loosely correlated with PTCT. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if GTBP jumps, then PTCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GTBP
1D Price
Change %
GTBP100%
+3.10%
PTCT - GTBP
35%
Loosely correlated
+5.63%
AMRN - GTBP
33%
Poorly correlated
-4.96%
MDGL - GTBP
32%
Poorly correlated
+0.21%
VKTX - GTBP
31%
Poorly correlated
+1.93%
BPMUF - GTBP
29%
Poorly correlated
N/A
More

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with VXRT. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then VXRT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
+0.21%
VXRT - MDGL
61%
Loosely correlated
-3.13%
ALXO - MDGL
56%
Loosely correlated
+0.66%
REPL - MDGL
55%
Loosely correlated
+5.66%
ZNTL - MDGL
51%
Loosely correlated
+1.32%
CGEM - MDGL
50%
Loosely correlated
+3.13%
More